(Q36009834)

11 August 2017

0 references

Efficacy of lumiracoxib in osteoarthritis: a review of nine studies (English)

1 reference

11 August 2017

1 reference

F Berenbaum

1

1 reference

11 August 2017

J Grifka

2

1 reference

11 August 2017

J P Brown

3

1 reference

11 August 2017

J Zacher

4

1 reference

11 August 2017

A Moore

5

1 reference

11 August 2017

G Krammer

6

1 reference

11 August 2017

D Dutta

7

1 reference

11 August 2017

V S Sloan

8

1 reference

11 August 2017

publication date

1 January 2005

1 reference

Journal of International Medical Research

11 August 2017

published in

1 reference

11 August 2017

volume

33

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

21-41

1 reference

Epidemiology of rheumatic diseases

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Update of ACR guidelines for osteoarthritis: role of the coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Is hirudin a potential therapeutic agent for arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of (NZBxW)F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Clodronate induced uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Pharmacokinetics of lumiracoxib in plasma and synovial fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Erdheim-Chester disease in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Raised serum interleukin 15 levels in Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Definition and epidemiology of osteoarthritis of the hand: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300102

10.1177/147323000503300102

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference